OKYO Pharma Limited

NasdaqCM:OKYO Stock Report

Market Cap: US$87.8m

OKYO Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of OKYO?
Owner TypeNumber of SharesOwnership Percentage
Institutions677,3831.32%
Hedge Funds4,058,4457.9%
Individual Insiders15,958,10431.1%
General Public30,676,26559.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.4%.

Top Shareholders

Top 17 shareholders own 40.28% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.8%
Gabriele Marco Cerrone
10,172,677US$17.4m0%no data
7.9%
Point72 Asset Management, L.P.
4,058,445US$6.9m0%0.01%
7.4%
Jorey Chernett
3,802,194US$6.5m27.4%no data
3.75%
Laura Fonda
1,928,451US$3.3m0%no data
0.92%
Dauntless Investment Group, Llc
471,523US$806.3k-80.5%2.29%
0.27%
Renaissance Technologies LLC
138,000US$236.0k235%no data
0.089%
Gary Jacob
45,833US$78.4k0%no data
0.034%
XTX Markets Limited
17,612US$30.1k0%no data
0.025%
Cerity Partners LLC
12,812US$21.9k0%no data
0.024%
Geode Capital Management, LLC
12,090US$20.7k0%no data
0.024%
FMR LLC
12,089US$20.7k-0.01%no data
0.019%
Wealth Enhancement Advisory Services, LLC
10,000US$17.1k0%no data
0.017%
Willy Simon
8,949US$15.3k0%no data
0.0042%
UBS Asset Management AG
2,172US$3.7k0%no data
0.0018%
EFG Bank AG
923US$1.6k0%no data
0.0003%
Osaic Wealth, Inc.
152US$263.50%no data
0.00002%
Morgan Stanley
10US$17.60%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/10 13:23
End of Day Share Price 2026/03/10 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OKYO Pharma Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William WoodB. Riley Securities, Inc.
Yi ChenH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets